UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

被引:7
|
作者
Diaz-Santa, Johana [1 ]
Rodriguez-Romanos, Rocio [1 ]
Osca, Gemma [1 ]
Pratcorona, Marta [2 ]
Garrido, Ana [2 ]
Coll, Rosa [1 ]
Moret, Carla [1 ]
Escoda, Lourdes [3 ]
Tormo, Mar [4 ]
Heras, Inma [5 ]
Arnan, Montse [6 ]
Vives, Susanna [7 ]
Salamero, Olga [8 ]
Lloveras, Natalia [1 ]
Bargay, Joan [9 ]
Sampol, Antonia [10 ]
Cruz, David [1 ]
Garcia, Antoni [11 ]
Quinones, Teresa [1 ]
Esteve, Jordi [12 ]
Sierra, Jorge [2 ]
Gallardo, David [1 ]
机构
[1] Univ Girona, Hematol Dept, Catalan Inst Oncol ICO, Inst Invest Biomed Girona IDIBGI, Girona, Spain
[2] Univ Autonoma Barcelona, Hosp Santa Creu i St Pau, Inst Invest Biomed St Pau, Hematol Dept, Barcelona, Spain
[3] Hosp Joan 23, Hematol Dept, Catalan Inst Oncol ICO, Tarragona, Spain
[4] Hosp Clin, Hematol Dept, Valencia, Spain
[5] Univ Hosp Morales Meseguer, Dept Hematol, Murcia, Spain
[6] Catalan Inst Oncol ICO, Dept Hematol, Barcelona, Spain
[7] Josep Carreras Leukemia Res Inst IJC, Hematol Dept, Catalan Inst Oncol ICO, Barcelona, Spain
[8] Hosp Vall dHebro, Hematol Dept, Barcelona, Spain
[9] Hosp Son Llatzer, Hematol Dept, Palma De Mallorca, Spain
[10] Hosp Son Espases, Hematol Dept, Palma De Mallorca, Spain
[11] Hosp Arnau Vilanova, Hematol Dept, Lleida, Spain
[12] Univ Barcelona, Hematol Dept, Inst Invest Biomed August Pi i Sunyer IDIBAP, Hosp Clin, Barcelona, Spain
关键词
ACUTE MYELOGENOUS LEUKEMIA; POLYMORPHISMS; MUTATIONS; CANCER; ADULTS; IMPACT; GENE; 1A1;
D O I
10.1038/s41375-020-0784-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The treatment of acute myeloid leukemia (AML) is adjusted according to cytogenetic risk factors and molecular markers. Cytarabine remains the main drug to treat AML, and several studies have explored the prognostic relevance of the genotype of cytarabine metabolizing enzymes in AML. Glucuronidation has been identified to be relevant in the cytarabine clearance, but there are still few data concerning the clinical impact of genetic polymorphisms known to condition the activity of UDP-glucuronosyl transferases in AML patients. Here we report the association between the UGT1A1 rs8175347 genotype and the clinical outcome of 455 intermediate-risk cytogenetic AML patients receiving cytarabine-based chemotherapy. Patients with the UGT1A1*28 homozygous variant (associated to a lower UGT1A1 activity) had a lower overall survival (OS) (25.8% vs. 45.5%;p: 0.004). Multivariate analysis confirmed this association (p: 0.008; HR: 1.79; 95% CI: 1.16-2.76). Subgroup analysis showed the negative effect of the UGT1A1*28 homozygous genotype on OS in women (14.8% vs. 52.7%;p: 0.001) but not in men. This lower OS was associated with longer neutropenia after consolidation chemotherapy and with higher mortality without previous relapse, suggesting an association between a low glucuronidation activity and mortal toxic events.
引用
收藏
页码:2925 / 2933
页数:9
相关论文
共 50 条
  • [41] Impact of UGT1A1 genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.
    Ichikawa, Wataru
    Uehara, Keisuke
    Minamimura, Keisuke
    Tanaka, Chihiro
    Takii, Yasumasa
    Miyauchi, Hideaki
    Sadahiro, Sotaro
    Shinozaki, Katsunori
    Fukumoto, Kanehisa
    Otsuji, Toshio
    Kambara, Takeshi
    Morita, Satoshi
    Ando, Yuichi
    Okutani, Yukihiro
    Sugihara, Masahiro
    Sugiyama, Toru
    Ohashi, Yasuo
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies
    Bertoli, Sarah
    Tavitian, Suzanne
    Berard, Emilie
    Gadaud, Noemie
    Luquet, Isabelle
    Huynh, Anne
    Sarry, Audrey
    Huguet, Francoise
    Recher, Christian
    LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 238 - 241
  • [43] A Novel Xenograft Model of Cytogenetically Normal Acute Myeloid Leukemia Harboring RUNX1 and ASXL1 Mutations Demonstrates Residual Disease after Anthracycline/Cytarabine-Based Chemotherapy
    Sivagnanalingam, Umayal
    Balys, Marlene
    Eberhardt, Allison
    Wang, Nancy
    Ashton, John M.
    Mendler, Jason H.
    BLOOD, 2014, 124 (21)
  • [44] UGT1A1*28/*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy
    Wong, Megan
    Behrendt, Carolyn E.
    Yu, Wai
    Bosserman, Linda D.
    Lavasani, Sayeh Moazami
    Patel, Niki
    Sedrak, Mina S.
    Stewart, Daphne B.
    Waisman, James Ross
    Yuan, Yuan
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups
    J. Y. Zhang
    K. Yu
    L. J. Li
    Clinical and Translational Oncology, 2019, 21 : 1543 - 1550
  • [46] Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups
    Zhang, J. Y.
    Yu, K.
    Li, L. J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11): : 1543 - 1550
  • [47] Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
    Fleischmann, Maximilian
    Schnetzke, Ulf
    Frietsch, Jochen J.
    Sayer, Herbert G.
    Schrenk, Karin
    Hammersen, Jakob
    Glaser, Anita
    Hilgendorf, Inken
    Hochhaus, Andreas
    Scholl, Sebastian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (06) : 1481 - 1492
  • [48] Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
    Maximilian Fleischmann
    Ulf Schnetzke
    Jochen J. Frietsch
    Herbert G. Sayer
    Karin Schrenk
    Jakob Hammersen
    Anita Glaser
    Inken Hilgendorf
    Andreas Hochhaus
    Sebastian Scholl
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1481 - 1492
  • [49] Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
    Fleischmann, M.
    Schnetzke, U.
    Frietsch, J.
    Sayer, H.
    Schrenk, K.
    Hammersen, J.
    Glaser, A.
    Hilgendorf, I
    Hochhaus, A.
    Scholl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 143 - 144
  • [50] Impact of UGT1A1 genotype on overall survival in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.
    Ichikawa, Wataru
    Uehara, Keisuke
    Minamimura, Keisuke
    Tanaka, Chihiro
    Takii, Yasumasa
    Miyauchi, Hideaki
    Sadahiro, Sotaro
    Shinozaki, Katsunori
    Fukumoto, Kanehisa
    Otsuji, Toshio
    Kambara, Takeshi
    Morita, Satoshi
    Ando, Yuichi
    Arai, Miyuki
    Sugihara, Masahiro
    Sugiyama, Toru
    Ohashi, Yasuo
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)